Astrazeneca Share News (AZN)

LONDON MARKET EARLY CALL: Stocks to fall but pound rises ahead of BoE

(Alliance News) - Stocks in London are set to open lower on Monday, with a Bank of England decision ahead, and as developments in US-China relations are also in focus.

Sell GBP on aggressive BoE pricing - Danske Bank

STOXX 600 up 0.6%

*

LONDON MARKET CLOSE: Europe mixed after ECB hike and hawkish Fed

(Alliance News) - London's FTSE 100 closed higher, though equities in mainland Europe weakened, after both the Federal Reserve and European Central Bank both hinted that they are not done with rate hikes.

AstraZeneca wins approval in China for Soliris in myasthenia gravis

(Alliance News) - AstraZeneca PLC on Tuesday announced another approval in China for Soliris to treat a rare neuromuscular disease.

Novartis buys Chinook for $3.5 bln in race to treat rare kidney disease

June 12 (Reuters) - Novartis said it has agreed to acquire U.S. biotech firm Chinook Therapeutics for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment.

AstraZeneca breast cancer drug capivasertib gets priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its breast cancer drug capivasertib in combination with breast-cancer treating hormone therapy drug faslodex has been granted priority review in the US for patients with advanced HR-positive breast cancer.

AstraZeneca gets new FDA RSV approval, partners with Quell

(Sharecast News) - AstraZeneca announced on Friday that the US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) had unanimously voted in favour of 'nirsevimab' as a preventive treatment for respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants.

TOP NEWS: AstraZeneca hails deal with Quell; positive danicopan data

(Alliance News) - AstraZeneca PLC on Friday reported positive phase 3 trial data for its oral drug danicopan and struck an agreement with London-based biopharma company Quell Therapeutics Ltd.

LONDON BRIEFING: Network International agrees to GBP2.2 billion buyout

(Alliance News) - Stocks in London were called to open higher on Friday, after a weak US jobless claims reading threw "cold water" over expectations for an interest rate hike by the Federal Reserve next week.

AstraZeneca hails RSV drug nirsevimab recommendation by FDA committee

(Alliance News) - AstraZeneca PLC on Thursday said that a US Food & Drug Administration committee unanimously recommended its antibody nirsevimab.

London stocks slip as global growth concerns weigh

Indivior jumps on U.S. Suboxone lawsuit settlement

*

AstraZeneca and Daiichi Sankyo report progress in cancer drug trials

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday reported positive results from trials of two cancer drugs, Enhertu and datopotamab deruxtecan.

AstraZeneca stops Andexxa trial early, Tagrisso reduces death risk

(Alliance News) - AstraZeneca PLC on Monday said its Andexxa phase four trial will be stopped early after achieving positive efficacy data.

AstraZeneca sees positive results for Imfinzi in gastric cancers

(Alliance News) - AstraZeneca PLC on Friday reported positive results from planned interim analysis of a phase three trial evaluating its Imfinzi drug in gastric and gastroesophageal junction cancers.

TOP NEWS: AstraZeneca discontinues brazikumab; Lynparza wins approval

(Alliance News) - AstraZeneca PLC on Thursday hailed another approval for cancer drug Lynparza, while it ceased its development programme for Crohn's disease-focused brazikumab.